ENvue Medical taps $50 million equity line as Series H preferred obligations expand
A $50 million committed equity facility sits at the center of FEED's August 12 current report, with the draw window gated on SEC registration statement effectiveness and an embedded obligation to redirect 40 percent of…
Key takeaways
- ENvue Medical signed a $50 million committed equity facility with an unnamed institutional investor on August 12, 2026, drawable only after the SEC declares its resale registration statement effective.
- The facility requires 40 percent of every net dollar raised to be redirected toward redeeming Series X Preferred Stock until none of that class remains outstanding.
- Under the facility, ENvue can direct the investor to buy shares at 90 percent of the lowest VWAP over the three trading days before each purchase date, with draws entirely at the company's discretion.
- A Second Amendment to the Series H Purchase Agreement raises Additional Investment Rights to $59 million in Stated Value, equal to 59,000 Series H preferred shares with a $53.1 million Subscription Amount.
- Subject to Shareholder Approval, the investor committed to exercise at least $10 million of Series H rights over 12 months, a monthly floor of $833,333.33.
A $50 million committed equity facility sits at the center of FEED's August 12 current report, with the draw window gated on SEC registration statement effectiveness and an embedded obligation to redirect 40 percent of every net dollar raised toward retiring Series X Preferred Stock. The next confirmable milestone is Shareholder Approval, which separately governs a restructured Series H preferred commitment that now carries a $10 million minimum exercise floor.
The equity facility mechanics
ENvue Medical, Inc. and an unnamed institutional investor signed a Common Shares Purchase Agreement on August 12, 2026. Under the terms, the company can direct the investor to purchase shares priced at 90 percent of the lowest volume weighted average price across the three trading days preceding each applicable purchase date. Draw timing rests entirely at the company's discretion. Nothing in the agreement compels ENvue to sell.
The facility runs for 36 months from Commencement. Commencement is defined as the date the SEC declares the initial resale registration statement effective and a final prospectus is filed. Until that happens, the $50 million is committed on paper, not accessible in practice.
The 40 percent Series X redemption earmark runs until no shares of that preferred class remain outstanding. Remaining proceeds go to working capital and general corporate purposes. ENvue can terminate the agreement at any time after Commencement on five trading days' written notice, at no cost or penalty.
Series H preferred: the second track
The filing also covers a Second Amendment to the Series H Purchase Agreement, the original dated July 18, 2025, and first amended January 30, 2026. The amendment increases the total Additional Investment Rights to $59 million in Stated Value. That converts to 59,000 shares of Series H Convertible Preferred Stock carrying a Subscription Amount of $53.1 million.
Subject to Shareholder Approval, the investor agreed to exercise no less than $10 million of those rights in the 12 months following approval. The monthly floor is $833,333.33. Certain fund-raising events reduce that minimum on a dollar-for-dollar basis.
What to watch
Both structures hinge on separate approval events. The equity line cannot draw until the SEC registration statement is declared effective. The Series H amendment terms, including the investor's minimum exercise commitment, do not activate until Shareholder Approval is received. Until that approval is in hand, the $833,333.33 monthly floor does not run.